Laboratory Monitoring for Patients on Rezdiffra (Resmetirom)
Check liver enzymes (ALT/AST) at 12 weeks after starting Rezdiffra to assess for hepatotoxicity, then monitor aminotransferases at 6 months for disease monitoring, and perform comprehensive efficacy assessment at 12 months and annually thereafter. 1
Structured Monitoring Timeline
Week 12: Safety Assessment (Initial Checkpoint)
Primary focus: Hepatotoxicity screening
- Liver enzymes (ALT/AST) - mandatory 1
- Early transient increases (<1.5x baseline) are expected, especially in patients on statins
- These typically resolve by week 8 without discontinuation
- Do NOT assess efficacy at this timepoint - changes in ALT do not accurately reflect treatment response 1
Critical pitfall: Avoid premature discontinuation based on mild ALT elevations at week 12, as the drug's mechanism causes expected early enzyme increases that normalize spontaneously 1
Month 6: Disease Monitoring
Aminotransferases should be checked 1
Optional imaging:
- VCTE (vibration-controlled transient elastography) or
- MRI-PDFF (proton density fat fraction)
Important caveat: Absence of response at 6 months is inadequate to fully assess treatment - reserve judgment until 12 months 1
Month 12 and Annually: Efficacy Monitoring
This is the definitive assessment timepoint 1
Required monitoring:
Aminotransferases (ALT/AST)
- Look for improvement (≥17 IU/L decrease or ≥20% improvement) or normalization 1
- If ALT stable but other markers improve, continue treatment
Liver stiffness measurement (LSM)
MRI-PDFF (if obtained at baseline)
- Treatment success: >30% reduction in liver fat 1
- This is the most predictive marker of histologic response
Additional Safety Monitoring
Thyroid Function Tests
Monitor in selected patients 2, 3
- Free T4 decreases by 13-17% at 12 months (expected pharmacologic effect) 3
- TSH and T3 remain within normal limits
- No clinical thyroid dysfunction observed in trials
- Resmetirom does not interfere with thyroid hormone replacement therapy 1
Sex Hormone-Binding Globulin (SHBG)
- Elevated SHBG reflects target engagement 2
120% increase associated with positive treatment response 2
- Free testosterone remains unchanged 1
Lipid Panel
- Monitor LDL-cholesterol (expect 14-20% reduction) 1
- Adjust statin dosing if needed per drug interactions
Treatment Discontinuation Criteria
Stop resmetirom if: 1
- Persistent significant liver enzyme elevation at any time
- Worsening in ≥2 noninvasive tests at 12 months:
30% increase in VCTE
20% increase in liver enzymes
- <30% improvement in MRI-PDFF (if baseline obtained)
- Drug intolerance (debilitating GI symptoms)
- No response in MRI-PDFF if obtained at baseline
Drug Interaction Monitoring
If patient on statins: 1
- Limit rosuvastatin/simvastatin to 20 mg/day
- Limit pravastatin/atorvastatin to 40 mg/day
- Monitor for statin-related adverse effects (though none observed in trials)
Avoid or adjust: 1
- Strong CYP2C8 inhibitors (gemfibrozil) - contraindicated
- Moderate CYP2C8 inhibitors (clopidogrel) - reduce resmetirom dose, monitor closely
- OATP1B1/1B3 inhibitors (cyclosporine) - contraindicated
Key Clinical Pearls
The 2024 expert panel guidelines emphasize a three-period assessment strategy 1:
- Week 12 = safety only
- Month 6 = disease monitoring (not definitive)
- Month 12+ = efficacy assessment
Most common adverse effects to monitor clinically 3:
- Diarrhea (33% at 100mg dose) - median onset 6-17 days, duration 20 days
- Nausea (15-22%) - median onset 5-28 days, duration 26-28 days
- Both are typically mild-moderate and self-limited
The evidence strongly supports that histologic improvements may occur without corresponding changes in VCTE or liver enzymes 1, emphasizing the importance of MRI-PDFF or considering liver biopsy before labeling patients as non-responders based solely on aminotransferases.